PAMP
LXEO icon

Polar Asset Management Partners’s Lexeo Therapeutics LXEO Stock Holding History

Polar Asset Management Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59,800
Closed -$541K – 752
2024
Q3 		$541K Sell
59,800
-5,500
-8% -$65.6K 0.01% 454
2024
Q2 		$1.05M Buy
+65,300
New +$948K 0.02% 388

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Polar Asset Management Partners's LXEO Position: Q4 2024 in Review

Polar Asset Management Partners sold out of Lexeo Therapeutics (LXEO) in Q4 2024, closing a stake of 59,800 shares — an estimated $541K sold.

Polar Asset Management Partners first reported a position in LXEO in Q2 2024 and held it in 2 quarters. The position peaked at $1.05M in Q2 2024. 90 funds tracked by Wall St. Rank hold LXEO as of Q4 2024.

  • Polar Asset Management Partners reported no remaining Lexeo Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 59,800 Lexeo Therapeutics shares in Q4 2024, an estimated $541K.
  • Polar Asset Management Partners first reported a position in Lexeo Therapeutics in Q2 2024 and held it in 2 quarters.
  • Polar Asset Management Partners's Lexeo Therapeutics position peaked at $1.05M in Q2 2024.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q4 2024.

Based on Polar Asset Management Partners's 13F filing for Q4 2024, filed 14 Feb 2025.